MBX Biosciences (MBX) Income from Continuing Operations (2023 - 2026)

MBX Biosciences has reported Income from Continuing Operations for 4 years, with the latest figure at 102028000.0 in Q1 2026.

• Quarterly Income from Continuing Operations fell 277.35% year-over-year to 102028000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 213654000.0 (down 181.93% YoY) and the FY2025 annual result came in at 184722000.0, down 78.69% from the prior year.
• Income from Continuing Operations slipped to 102028000.0 in Q1 2026 per MBX's latest filing, from 14910000.0 in the prior quarter.
• Over five years, Income from Continuing Operations peaked at 10936000.0 in Q3 2023 and troughed at 102028000.0 in Q1 2026.
• A 4-year average of 29848181.82 and a median of 16770000.0 in 2024 frame the typical range for Income from Continuing Operations.
• The sharpest annual moves came in 2024 and 2026: Income from Continuing Operations gained 13.78% in 2024, then tumbled 277.35% in 2026.
• Over 4 years, Income from Continuing Operations stood at 14480000.0 in 2023, then grew by 13.78% to 12484000.0 in 2024, then decreased by 19.43% to 14910000.0 in 2025, then slumped by 584.29% to 102028000.0 in 2026.
• According to Business Quant data, Income from Continuing Operations over the past three periods registered 102028000.0, 14910000.0, and 61935000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.